美醫保索償處理企業MSP透過SPAC上市 為史上第二大宗SPAC併購
美國醫保索償處理企業MSP Recovery將透過與特殊目的收購公司(SPAC)Lionheart Acquisition Corp II (LACP.US)合併實現上市,合併後公司估值326億美元,為歷來第二大宗特殊目的收購公司併購。MSP Recovery將於是次合併中取得2.3億美元現金。
MSP Recovery收集及分析政府支持的Medicare及Medicaid醫保索償,為醫院、醫療保險商及醫療供應商取回款額。創辦人指政府醫保索償支付大量不應支付的索償,損害納稅人利益。公司透過成功取回款額收取費用。是次上市集資將用作購買索償組合,並進一步強化數據分析能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.